BiotechTube

Telaprevir + Ribavirin + Pegylated Interferon Alfa-2a

ApprovedTerminated
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hepatitis C

Conditions

Hepatitis C

Trial Timeline

Jan 1, 2012 → May 1, 2014

NCT ID
NCT01467492

About Telaprevir + Ribavirin + Pegylated Interferon Alfa-2a

Telaprevir + Ribavirin + Pegylated Interferon Alfa-2a is a approved stage product being developed by Vertex Pharmaceuticals for Hepatitis C. The current trial status is terminated. This product is registered under clinical trial identifier NCT01467492. Target conditions include Hepatitis C.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT01467492ApprovedTerminated

Competing Products

20 competing products in Hepatitis C

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
47
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
49
TERN-101Terns PharmaceuticalsPhase 2
49
TERN-201Terns PharmaceuticalsPhase 1
30
IVA337 + IVA337 + PlaceboInventivaPhase 2
47
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
47
IVA337 + PlaceboInventivaPhase 3
72
Pegasys® + Pegasys®Chugai PharmaceuticalApproved
85
peginterferon alfa-2a + rivavirinChugai PharmaceuticalPhase 3
77
SOF + COPEChugai PharmaceuticalPre-clinical
23
Colesevelam HclDaiichi SankyoPhase 2
52
ASP9831 + PlaceboAstellas PharmaPhase 2
52
FK788Astellas PharmaPhase 2
52
MK-2248MerckPhase 1
33
Interferon alfacon-1Astellas PharmaPhase 3
77
Pegylated Interferon + RibavirinAstellas PharmaApproved
85
Tacrolimus + steroids, monoclonal anti-IL2R antibodyAstellas PharmaPhase 2
52
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
33
Dolutegravir + MethadoneShionogiPhase 1
33
Clevudine + AdefovirEisaiPhase 3
77

Other Products from Vertex Pharmaceuticals

LUM/IVAApproved
84
suzetrigineApproved
84
SuzetrigineApproved
84
LUM/IVA + PlaceboApproved
84
SuzetrigineApproved
84